SCHEMBL17796530

SCHEMBL17796530

Cc1cc(Cl)ncc1C(=O)N1CCOCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.56
▸ LMNA P02545 2/20 0.52
▸ HTT P42858 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ HSP90AA1 P07900 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ PKM P14618 2/20 0.48
▸ PHGDH O43175 1/20 0.48
▸ CNR1 P21554 3/20 0.47
▸ CNR2 P34972 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ LRRK2 Q5S007 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17804187 0.85 HPGD (0.48) HPGDHTTTSHRHSP90AA1CNR1
SCHEMBL5079739 0.82 HSP90AA1 (0.56) HPGDLMNAHTTMAPTTSHR
SCHEMBL17796415 0.81 PIK3CA (0.41) —
SCHEMBL19651830 0.81 HSP90AA1 (0.51) HPGDLMNAHTTMAPTTSHR
SCHEMBL19657114 0.80 MAPT (0.58) HPGDLMNAHTTMAPTTSHR
SCHEMBL17796521 0.77 RAB9A (0.44) HPGDLMNALRRK2
SCHEMBL17796420 0.77 RAB9A (0.44) HPGDLMNALRRK2
SCHEMBL17796675 0.75 KMT2A (0.48) HPGDLMNAHSP90AA1PKMSMN1; SMN2
SCHEMBL17796440 0.75 KMT2A (0.48) HPGDLMNAHSP90AA1PKMSMN1; SMN2
SCHEMBL2072292 0.75 SMN1; SMN2 (0.70) HPGDMAPTKDM4EPKMPHGDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 — — US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 — — US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 — — US disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 — — EP disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159773-A1 HETEROCYCLIC COMPOUND TYK2, SSB, UACA HPGD 3414/4885LMNA 2866/4885HTT 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback